





Population pharmacokinetic modelling for dose optimization of esomeprazole to 




MANNA SEMERE GEBREYESUS 
SMRMAN003 
SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
 
In partial fulfilment of the requirements for the degree 
MPhil (Clinical Pharmacology) 
 
 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
 
 
Date of Submission: 28/09/2020 
 
Supervisors: Paolo Denti and Roeland Wasmann 




















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 













I, MANNA SEMERE GEBREYESUS, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where acknowledgements indicate 
otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted 
for another degree in this or any other university. This work has not been reported or published prior 
to registration for this degree. This thesis has been submitted to the Turnitin module. 
I empower the university to reproduce for the purpose of research either the whole or any portion 
of the contents in any manner whatsoever. 
























Esomeprazole is a proton pump inhibitor with preclinical efficacy data showing it lowers 
concentrations of soluble fms like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng), 
pathognomonic biomarkers identified in preeclampsia. A randomized controlled trial, Preeclampsia 
Intervention with Esomeprazole (PIE) trial, was conducted in South African women diagnosed with 
early-onset preeclampsia to investigate efficacy, but it found no change in clinical outcome or 
biomarker concentrations. It was hypothesized that the 40 mg daily oral dose was not enough to 
achieve therapeutic exposure. This study investigated the pharmacokinetics of esomeprazole in 
patients with early- onset preeclampsia with the aim to optimize the dose for future clinical trials. 
Methods 
Pharmacokinetic data from ten pregnant patients with early-onset preeclampsia from the PIE trial, 
median (range) age 30 (21-43) years, weight 98.8 (56-126) kg, and gestational age 29 (26- 31) 
weeks, were included for model development. In addition, pharmacokinetic data from non- pregnant 
healthy volunteers consisted of a pooled dataset of 26 male and female subjects, median (range) age 
of 21 (18-27) years and weight 69 (54-89) kg, who received 40 mg esomeprazole daily. Analysis of 
the pharmacokinetic data in pregnant patients was performed using nonlinear mixed-effects 
modelling with allometric scaling on clearance (CL) and volume  of distribution (Vd). Metabolite 
to parent area under the time-concentration curve  (AUCsulf/AUCeso and AUChyd/AUCeso)  ratios 
were compared between pregnant and non-pregnant to assess metabolic changes in pregnancy. 
Simulations were performed with the model to determine the nonlinear increase in AUC with higher 
doses and with repeated dosing in the pregnant patients. Simulation results were compared with the 
preclinical target unbound concentration (0.917 mg/L) and preclinical target unbound AUC0-24 (9.29 
mg·h/L). 
Results 
A one compartment pharmacokinetic model with first-order elimination and transit compartment 
absorption best described the data. Model estimated apparent CL and apparent Vd (95% CI) were 
19.2 (14.2-26) L/h and 44.2 (29.9-56.6) L, respectively. Median AUCsulf/AUCeso (IQR) for pregnant 
patients, 2.00 (1.35-2.61) , was significantly higher  than that for non-pregnant subjects on day1, 
0.700 (0.636-1.00) , and day5, 1.18 (0.981- 1.58) . Median AUChyd/AUCeso (IQR) for pregnant 
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patients, 0.0543 (0.0500-0.0914) , was not significantly different from that of non-pregnant subjects 
on day5, 0.0777 (0.0569-0.108)  but lower than that of non-pregnant subjects on day1, 0.188 (0.156- 
0.227). Simulation results showed that predicted steady state unbound Cmax is between 0.0949 and 
0.398 mg/L while the predicted unbound AUC0-24 in pregnant patients with the highest dose of 
esomeprazole used clinically, i.e.120 mg BID, is between 0.696 and 2.92 mg·h/L. 
Discussion/Conclusion 
Model estimated CL/F and Vd/F are higher than values previously reported by other population 
pharmacokinetic models. AUCm/AUCp comparisons showed that esomeprazole metabolism in 
pregnancy appears to have shifted to the CYP3A4 pathway. This means that the nonlinear AUC 
increase expected with dose escalation and with repeated dosing are not as significant as in non-
pregnant. Simulations indicate that pregnant patients are unlikely to achieve the target concentration 
and exposure with the highest dose of esomeprazole registered. Further research  is necessary to 
determine the target site of action of esomeprazole in preeclampsia, and the pharmacokinetic metric 
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Preeclampsia is a disorder of pregnancy which is observed after 20 weeks of gestation and resolves 
within 6 weeks of delivery. The global incidence of preeclampsia is 3% to 8%, and it is estimated 
to cause 60,000 maternal and 500,000 foetal deaths annually (Marshall et al., 2019). The incidence 
of preeclampsia is seven times higher in developing countries and preeclampsia-related maternal 
mortality is also higher, 15% compared to 1.8% or less in developed countries (Ghulmiyyah and 
Sibai, 2012; Armaly et al., 2018). Maternal risk factors for preeclampsia include: age below 20 
years or above 35 years; obesity; first or multiple pregnancies; family history of preeclampsia; 
preeclampsia in a previous pregnancy; ethnicity (black women are more at risk); history of 
metabolic, cardiovascular, or autoimmune diseases; assisted pregnancy (e.g. in vitro fertilization, 
artificial insemination), and interval between pregnancies of more than 10 years (English, Kenny 
and McCarthy, 2015). 
8.2 Pathogenesis 
In normal pregnancies during placental development (weeks 8 to 20), placental cells called 
cytotrophoblasts invade the uterine wall and migrate to the spiral arteries, vessels that line that 
uterus. Cytotrophoblasts differentiate as they migrate to mimic the structure and molecular signaling 
of vascular endothelial cells which enables them to remodel the endothelial lining and smooth 
muscle of maternal spiral arteries. As a result, the spiral arteries become low resistance vessels that 
can handle high volume blood flow to augment blood supply to the placenta and meet the increasing 
needs of the growing foetus (Figure 1). Proteins released by cytotrophoblasts to facilitate the 
remodeling process include antiangiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-
1) and soluble endoglin (sEng), and proangiogenic factors such as placental growth factor (PIGF) 
and vascular endothelial growth factor (VEGF). sFlt-1 concentrations are increased by 20-fold in 
the maternal circulation in the third trimester of normal pregnancies compared to non-pregnant 
women (Shibata et al., 2005). 
In preeclampsia, migration of cytotrophoblasts into the uterus is shallow and spiral arteries are only 
partially modified or not modified at all (Figure 1). In some cases, the number of cytotrophoblasts 
seem to be reduced and in others, cytotrophoblasts do not seem to adequately mimic the properties 
of endothelial cells. The underlying reason for the altered behavior of placental cells in preeclampsia 
is unknown, but a combination of genetic (altered differentiation of early trophoblast cells) and 
immunologic (exaggerated maternal response) factors are implicated (Huppertz, 2008). As a result, 
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the placenta becomes hypoxic and suffers oxidative stress, releasing inflammatory cytokines and 
free radicals. Antiangiogenic soluble factors are upregulated in the hypoxic placenta, a process 
mediated by hypoxia inducible factor 1α (HIF- 1α), and their secretion into the maternal circulation 
is increased. sFlt-1 and sEng have been reported to be 3-fold higher in the maternal circulation in 
preeclamptic pregnancies compared to normal pregnancies (Shibata et al., 2005).
Figure 1. Physiological transformation of maternal spiral arteries in normal pregnancy (left) 
and preeclamptic pregnancy (right). In preeclamptic pregnancies, trophoblast invasion of 
the spiral arteries is shallow and does not extend into the myometrium, resulting in lack of 
adequate transformation (Adapted from (Chaiworapongsa et al., 2014) 
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sFlt-1 and sEng have been linked to the maternal endothelial dysfunction in preeclampsia in mouse 
models (Maynard et al., 2003; Venkatesha et al., 2006). Their concentrations are directly correlated 
to the severity of preeclampsia and decrease postpartum (Leaños-Miranda et al., 2017). sFlt-1 is a 
circulating splice variant of the vascular endothelial receptor, fms like tyrosine kinase 1 (Flt-1), 
which binds to VEGF. VEGF and PIGF signalling at the Flt-1 receptor is coupled to endothelial 
nitric oxide synthase (eNOS) and leads to production of nitric oxide (NO), a vasodilator. sFlt-1 
binds to and sequesters VEGF and PIGF, preventing their signalling at their receptors. It also 
sensitizes vascular endothelial cells to inflammatory cytokines such as tumour necrosis factor-α 
(TNF- α) and to pro-constrictive factors such as endothelin 1 (ET- 1) leading to vascular 
inflammation and vasoconstriction. sEng is a circulating splice variant of endoglin, a coreceptor for 
signalling of transforming growth factor β (TGF- β) and sequesters TGF- β, producing effects 
similar to that of sFlt-1. PIGF secretion by the placenta is lower in preeclampsia, and its 
concentration in the maternal circulation is 2.5-fold lower compared to normal pregnancies (Shibata 
et al., 2005). sFlt-1 to PIGF ratio greater than 38 is positively predictive for severity of 
preeclampsia, in the subsequent 4 weeks since measurement, and reduces the time needed for 
diagnosis (Zeisler et al., 2016; Müller et al., 2019). 
8.3 Symptoms 
The angiogenic imbalance induced by the preeclamptic placenta, i.e. the upregulation of sFlt- 1 and 
sEng coupled with the downregulation and sequestering of PIGF and VEGF, leads to systemic 
inflammation, activation of the coagulation system, and endothelial dysfunction in the maternal 
vasculature. This endothelial dysfunction is marked by a vasoconstrictive state and many organs 
are affected such as the brain, the kidneys, the lungs, the liver, and the heart. Symptoms indicating 
onset of preeclampsia include hypertension (≥ 140/90 mmHg) and signs of organ damage, such as 
proteinuria (≥ 300 mg within 24 h urine) at gestational age (GA) greater or equal to 20 weeks. Other 
accompanying symptoms such as headaches, visual disturbances, oedema, vomiting, and right 
upper quadrant abdominal pain could occur. Effects on the foetus include restriction of growth and 
placental abruption, leading to still birth (Steegers et al., 2010). To prevent maternal mortality, 
preterm delivery might be necessary, and this leads to neonatal complications such as respiratory 
distress, cerebral palsy, retinopathy associated with prematurity, and even death (Armaly et al., 
2018). 
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Preeclampsia is a progressive disorder and symptoms can range from mild to severe. Symptoms of 
severe preeclampsia include severe hypertension (≥ 160/110 mmHg); severe proteinuria ( ≥ 5 g 
within 24 h urine); hemolysis, elevated liver enzymes, and low platelet count (HELLP syndrome); 
disseminated intravascular coagulation (DIC), and eclampsia (seizures and coma during pregnancy 
unexplained by other conditions).  
Preeclampsia is associated with at least double the   risk of long-term maternal complications such 
as cardiovascular diseases, neurologic diseases, and diabetes mellitus (English, Kenny and 
McCarthy, 2015). 
8.4 Early- and late-onset preeclampsia 
In addition to disease severity, morbidity and mortality in preeclampsia are also correlated with GA 
at which it develops. Preeclampsia is classified as ‘early-onset’ when it occurs before 34 weeks and 
‘late-onset’ when it occurs after 34 weeks of GA. Early-onset preeclampsia comprises less than 
20% of all preeclampsia cases globally. It has higher risk of progressing to severe disease and has 
poorer foetal outcomes, being more associated with impaired uterine blood flow, foetal growth 
restriction, and preterm delivery (Huppertz, 2008; Hall, 2016). Late- onset preeclampsia is 
associated more with maternal morbidity due to metabolic and cardiovascular diseases with less 
foetal involvement (Huppertz, 2008; Raymond and Peterson, 2011; Armaly et al., 2018). 
8.5 Prevention 
Preeclampsia cannot be prevented, but severe outcomes can be reduced. Women at risk of 
preeclampsia are advised to make lifestyle changes before pregnancy, such as dietary changes and 
smoking cessation to modify metabolic risk factors and adequately manage chronic diseases. 
Regular prenatal care is needed to detect preeclampsia before it becomes severe. Low dose aspirin, 
75  mg per day, 12 to 36 weeks of GA has been recommended for women with one or more risk 
factors to prevent incidence of severe preeclampsia (Sammour et al., 2011). Safety of using aspirin 
at doses above 100 mg for prevention of severe preeclampsia has not been confirmed (Atallah et 
al., 2017).  Calcium supplementation,  at doses of 1.5 to 2 g per day from 20 weeks of gestation 
onwards, has been recommended by the World Health Organization (WHO) to prevent severe 
preeclampsia, especially in high risk populations (Sammour et al., 2011; Omotayo et al., 2016) . 
Both aspirin and calcium reduce vasoconstriction and aspirin stabilizes platelet activity, reducing 
coagulative complications (U.S. Preventive Services Task Force, 2015). 
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8.6 Treatment 
When mild preeclampsia is diagnosed at less than 32 weeks of GA, hospitalization and expectant 
management is recommended. This is to maintain balance between managing maternal clinical 
symptoms and gaining gestation age in order to prevent premature birth. For every day of gestation 
gained between 23 and 32 weeks, foetal survival is improved by 1% (proteinuria, liver enzymes, 
platelet count, and symptoms indicating preeclampsia progression, such as severe headaches and 
visual changes, and foetal assessment for growth and movement are done daily. Patients are treated 
with antihypertensives if hypertension is severe, with magnesium sulphate to reduce the risk of 
eclampsia, and with steroids to facilitate foetal lung development. Delivery is indicated at 34 weeks 
if symptoms are stable, but if there are signs of severity delivery is required even before 34 weeks. 
For severe preeclampsia diagnosed at 32 to 36 weeks of GA, hospitalization and expectant 
management is indicated as above, and delivery is at 37 weeks unless foetal/maternal condition is 
unstable. Although delivery of the placenta is the only curative treatment of preeclampsia, maternal 
monitoring is continued post- partum since complications might arise (Hall, 2016). 
8.7 Proton pump inhibitors for preeclampsia 
Proton pump inhibitors (PPIs) are a class of drugs which are used for gastric acid-related disorders. 
Omeprazole, the first-in-class drug, was first marketed in 1989. All PPIs act by blocking the last 
step in gastric acid secretion through inhibition of the H+/K+-ATPase enzyme (proton pump) found 
in the gastric parietal cells (Holt and Howden, 1991; Strand, Kim and Peura, 2017). These drugs 
have been used in all age groups and safely used by pregnant women for gastrointestinal disorders 
(Pasternak and Hviid, 2010; Matok et al., 2012). During the search for treatment that could reverse 
or quench the pathogenesis of preeclampsia, it was identified that PPIs could be potential candidates 
(Onda et al., 2015, 2017). 
In addition to their inhibition of acid secretion, it was observed that PPIs have anti- inflammatory 
actions (Wandall, 1992; Yoshida et al., 2000; Ichikawa et al., 2004). It was also shown that one of 
the PPIs, lansoprazole, upregulated Hemoxygenase-1 (HO-1), an enzyme of the hemoxygenase 
system, in gastric epithelial cells in rats (Takagi et al., 2009). There are reports that the 
hemoxygenase system could be involved in the pathogenesis of preeclampsia (George and Granger, 
2013). HO-1 is induced during oxidative stress and has protective biological functions. In 
pregnancy, it regulates placental development and reduces production of sFlt-1 and sEng, but its 
expression might be lower in preeclamptic placental cells (Ahmed et al., 2000; Cudmore et al., 
2007; Ramma and Ahmed, 2014). This led to the hypothesis that HO-1 production inducing drugs 
could be useful in preeclampsia. However, other reports have found that HO-1 expression is not 
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lower in preeclampsia, nor does it regulate sFlt-1 and sEng production (BARBER et al., 2001; Tong 
et al., 2015). 
Laboratory studies were conducted to investigate the efficacy of PPIs in preeclampsia (Onda et al., 
2015, 2017). Tissues that are known to be sources of  antiangiogenic biomarkers namely, isolated 
cells and explant tissue from the placenta, umbilical vein endothelial cells, and whole blood vessel 
explants were obtained from women with early-onset preeclampsia at delivery. These tissues were 
exposed to PPIs  at concentrations ranging from 5 to 100 µM. The PPIs investigated were 
lansoprazole, omeprazole, pantoprazole, rabeprazole, and esomeprazole. Biomarker concentrations 
were measured in the media after 24 hours (Onda et al., 2017). It was observed that the PPIs tested 




Esomeprazole was seen to be the most potent of the PPIs tested for reduction of sFlt-1 and sEng. 
Additional findings of the study (Onda et al., 2017) were that the PPIs tested: 
 Upregulated expression of the proangiogenic biomarker vascular VEGF (but did not affect 
PIGF) 
 Vasodilated whole blood vessels from preeclamptic pregnancies in ex vivo experiments 
 Decreased blood pressure in mice models of preeclampsia in in vivo experiments (through 
reduction of ET-1 secretion) 
Figure 2. Relative sFlt-1 (left) and sEng (right) concentrations in the media after 24-hour 
treatment with PPIs administered to primary placental cells. lans= lansoprazole, 
rab=rabeprazole, eso=esomeprazole. The blue bars indicate 5, 50, and 100 µM 
concentrations for each drug. Black bar indicates untreated control (Adapted from (Onda 
et al., 2017)) 
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 Reduced endothelial dysfunction by reducing secretion of inflammatory factors in in vitro 
experiments. 
The underlying molecular mechanisms of these effects, i.e. the targets or receptors at which PPIs 
act, could not be elucidated in this study. It is the opinion of the authors that these effects are not 
mediated through an induction of HO-1 although this is what initially led to the investigation into 
PPIs. These results led to the conclusion that PPIs could indeed be candidates for preeclampsia and 
that conducting a clinical trial with esomeprazole, the most potent PPI for these effects, would be 
justified (Tong et al., 2015; Onda et al., 2017). 
A prospective study of a cohort of pregnant women with confirmed or suspected preeclampsia 
conducted in the Netherlands corroborated the above findings. At the time of blood sampling for 
biomarker measurement, the women were taking esomeprazole (20 or 40 mg daily dose), 
omeprazole (10, 20, or 40 mg daily dose), or pantoprazole (20 or 40 mg daily dose). PPI use in this 
group of patients was associated with lower concentrations of sFlt-1 and sEng as well as lower ET-
1 concentrations. There was no effect on PIGF concentrations (Saleh et al., 2017). 
Another cohort study used data of pregnant women from the Swedish registry to identify if there 
was association between PPI use and preeclampsia subtypes, i.e. early-onset versus late- onset 
preeclampsia. The authors reported that there was increased association of PPI use in all trimesters 
and preeclampsia with term delivery, i.e. delivery after 37 weeks. However, this association was 
not found for preeclampsia with preterm delivery, i.e. delivery at less than 34 weeks or less than 37 
weeks, nor with preeclampsia with small for gestational age (SGA) foetus. PPI use during the third 
trimester was seen to lower the risk of preeclampsia with preterm delivery, especially delivery 
before 34 weeks, and with SGA foetus. The authors noted that this could have been because the 
highest increase in concentrations of antiangiogenic biomarkers (sFlt-1 and sEng) is observed in the 
third trimester close to disease onset (Hastie et al., 2019). These findings pointed out the potential 
of using PPIs during the third trimester especially for early-onset preeclampsia where preterm 
delivery is a major concern. 
All the above results led to the conclusion that a clinical trial would need to be conducted to confirm 
the efficacy of PPIs in this group of patients, i.e. whether PPIs could prolong gestation, improve 
maternal and foetal clinical outcomes, and reduce secretion of antiangiogenic biomarkers. 
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8.8 Preeclampsia intervention with esomeprazole (PIE) trial 
The PIE trial was a phase II double-blind, randomized, placebo-controlled clinical trial conducted 
in Tygerberg Hospital, South Africa. The aim of this trial was to see if once-daily 40-mg oral 
esomeprazole would be effective in treating early-onset preeclampsia. 120 pregnant women with 
GA between 26 and 31 weeks and diagnosed with early-onset preeclampsia received either 
esomeprazole or placebo (Cluver et al., 2015). Results of the trial showed that there was no 
significant difference between treatment and placebo arms for prolongation of pregnancy and for 
maternal/foetal/neonatal outcomes. There was no significant difference in the expression and 
concentrations of antiangiogenic (sFlt-1 and sEng)/proangiogenic (PGF/VCAM-1)/endothelial 
dysfunction (ET-1) biomarkers between the two arms (Cluver et al., 2018). 
It is unclear why the trial had negative results for all outcomes assessed when previous cohort 
observational studies in preeclampsia patients had shown that at standard clinical doses PPI use was 
associated with lower antiangiogenic biomarker concentrations (Saleh et al., 2017). A possible 
reason for this could be that esomeprazole, at 40 mg dose, is unable to alter the fate of preeclampsia 
once it has progressed, but there is still a chance that it might do so preventatively, which would 
need to be further studied (Cluver et al., 2018). The results of the PIE trial are also unexpected, 
given the preclinical studies by Onda et al. (Onda et al., 2017). The authors of the PIE trial believe 
that by achieving exposure similar to that in the preclinical study by Onda et al (Onda et al., 2017) 
through higher dosing, esomeprazole could show efficacy in this patient group. 
Sandrim et al. have expressed concerns regarding investigation of PPIs at high doses for 
preeclampsia, especially for patients who have a cardiovascular risk. Their concern is that PPIs are 
associated with increased risk of adverse cardiovascular events due to interference with the 
synthesis and homeostasis of nitric oxide (NO), an endothelium derived factor that relaxes blood 
vessels (Sandrim, Caldeira-Dias and Montenegro, 2019). However, in the preclinical study 
investigating efficacy of PPIs for treatment of preeclampsia, Onda et al (Onda et al., 2017) had 
shown that esomeprazole increased activity of the enzyme that synthesizes NO. They have shown 
that esomeprazole mitigates vascular damage produced by preeclampsia through pathways other 
than NO, such as by decreasing sFlt-1 and sEng, endothelin-1, and proinflammatory cytokines. 
They also showed PPIs vasodilated whole blood vessels in ex vivo studies and caused reduction of 
blood pressure in animal models of preeclampsia  (Onda et al., 2017). Additionally, in the PIE trial, 
there was no evidence that the treatment group had worse blood pressure.  
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Figure 3 shows summary pharmacokinetic profiles of esomeprazole and its metabolites in 10 
patients from the treatment arm of the PIE trial who underwent pharmacokinetic sampling. 
Esomeprazole geometric mean (95% confidence interval or CI) Area Under the Curve (AUC), 5.88 
(2.96-11.68) µmol·h/L, was reported to be similar to that of healthy, non-pregnant subjects, 4.32 
(3.04-6.14) µmol·h/L (Hassan-Alin et al., 2000). 
 
 
This project used pharmacokinetic data from this trial to investigate the population 
pharmacokinetics of esomeprazole in pregnant patients with early-onset preeclampsia in order to 
investigate higher doses to be used in future clinical trials. 
8.9 Pharmacokinetics of esomeprazole 
8.9.1 Introduction 
All PPIs have the same mechanism of action for their gastric acid inhibitory effect but differ in their 
pharmacokinetics and in the extent to which they produce their effect. PPIs are substrates of 
CYP3A4 and CYP2C19. Differences in pharmacokinetics among the PPIs are due to the extent to 
which they are metabolized by CYP2C19. For a PPI, interindividual variability in pharmacokinetics 
is attributed primarily to polymorphism in CYP2C19. Other factors that result in pharmacokinetic 
variability include meal times in relation to PPI dosing, which affect absorption, and concomitant 
administration of other drugs, which might also alter absorption or clearance (Andersson, Röhss, et 
al., 2001; El Rouby, Lima and Johnson, 2018). 
  
Figure 3. Esomeprazole and metabolite pharmacokinetics (geometric mean with 95% CI 
error bars) profiles of 10 patients from the PIE trial (Adapted from (Cluver et al., 2018)). 
10  
8.9.2 Formulation 
Esomeprazole is the S-isomer of omeprazole. It is a weak base and is acid labile, hence for oral 
route it is available in formulations that protect it from the gastric environment. Oral solid dosage 
forms are available in capsule or multi-unit pellet system (MUPS) tablet formulations. Both 
formulations contain enteric coated pellets and are expected to disintegrate in the stomach, after 
which they transport to the small intestine where they dissolve and are absorbed. Esomeprazole is 
also available for administration by the intravenous (IV) route (Strand, Kim and Peura, 2017; El 
Rouby, Lima and Johnson, 2018). 
8.9.3 Absorption, Distribution, Metabolism, and Excretion 
Esomeprazole is a highly albumin-bound drug (97%) with a short half-life of 1 to 1.5 hours. Protein 
binding is constant at a concentration range of 2 to 20 µM (0.691 to 6.91 mg/L), which is the 
concentration range it is expected to have in humans. It has fast absorption, achieving a Cmax of 0.8 
to 1.7 mg/L at 1 to 3.5 hours (Tmax) after a single oral dose of 40 mg without food. On single dosing, 
its bioavailability is 64% and its  Vd is 16 L. 80% of esomeprazole is renally excreted as metabolites, 
1% of the parent drug is renally excreted unchanged, and the remaining is excreted by the biliary 
route (El Rouby, Lima and Johnson, 2018). 
Esomeprazole is metabolized by CYP2C19 and by CYP3A4. CYP3A is the predominant CYP 
subfamily in the small intestine and constitutes ~80% of total intestinal CYP (Dressman and Thelen, 
2009). Esomeprazole has higher affinity for CYP2C19 (Michaelis constant or Km = 5µM) than for 
CYP3A4 (Km = 80 µM) (Andersson, Hassan-Alin, et al., 2001). As a result, after single dosing, 
two-third is metabolized by CYP2C19 to 5-hydroxy and 5-O-desmethyl esomeprazole and one-
third by CYP3A4 to esomeprazole sulfone. Esomeprazole sulfone is the    most prominent 
metabolite in plasma and is further metabolized by CYP2C19 to esomeprazole hydroxy sulfone 
(Figure 4). The metabolites are inactive for gastric acid inhibitory effects, and it is unknown if they 
have effect in preeclampsia.  
CYP2C19 is a polymorphic enzyme. Clearance (CL) of esomeprazole varies by CYP2C19 
genotype, with extensive metabolizers having at least 3 times higher CL than poor metabolizers 
(Dean, 2019). Ethnic differences in frequency of CYP2C19 polymorphisms exist. Asians have been 
reported to have the highest frequency of poor metabolizer phenotypes, 15 to 25%, compared to 
Caucasians and Africans, 3 to 5 % (Masimirembwa and Hasler, 1997; Dandara et al., 2001). 
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With repeated dosing, CYP2C19 is inhibited by esomeprazole and by its sulfone metabolite, which 
results in increased bioavailability and decreased clearance (Andersson, Hassan-Alin, et al., 2001; 
El Rouby, Lima and Johnson, 2018). Esomeprazole concentrations increase, hydroxy and desmethyl 





There is little change in AUC with repeated dosing in poor CYP2C19 metabolizers since 
metabolism is dependent on CYP3A4. On the other hand, AUC increases in extensive metabolizers 
with repeated dosing (Andersson, Hassan-Alin, et al., 2001). 
8.9.4 Nonlinear pharmacokinetics and auto-inhibition 
The pharmacokinetics of esomeprazole present a nonlinear dose-exposure relationship. As dose 
increases, AUC increases more than proportionally, which indicates a saturation of clearance and/or 
first-pass metabolism with increasing doses. Additionally, esomeprazole AUC increases with 
repeated dosing due to a decrease in clearance and an increase in bioavailability, which is due to 
autoinhibition of CYP2C19 (Andersson, Hassan-Alin, et al., 2001). Most previous studies of 
esomeprazole pharmacokinetics determined concentrations on day five of repeated dosing, hence 
day5 will be used in this work to consider the effect of repeated dosing. 
In healthy, non-pregnant subjects, with single dosing, AUC increases almost linearly from 5 to 20 
mg and nonlinearly from 20 mg onwards which indicates presence of saturation at high doses (Table 
Figure 4. Metabolic pathway of esomeprazole and autoinhibition of CYP2C19 with 
repeated dosing. 
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1) . With repeated dosing, AUC increases nonlinearly from the lowest dose, i.e. 5 mg (Andersson, 
Hassan-Alin, et al., 2001; Andersson, Röhss, et al., 2001). 
 
Table 1. AUC ratios, geometric mean (95% confidence interval), in healthy non-pregnant subjects for day 
1 and day 5 of dosing. (Adapted from (Hassan-Alin et al., 2000; Andersson, Röhss, et al., 2001)). 
 AUC (mg·h/L)  
Dose, 
oral solution 
Day 1 Day 5 Day 5/ day 1 ratio 
5 mg 0.100  
(0.065 – 0.15) 
0.113 
 (0.0760 – 0.169) 
1.14 (0.97 – 1.35) 
10 mg 0.225  
(0.145 – 0.349) 
0.339 
 (0.228 – 0.504) 
1.51 (1.27 – 1.78) 
10 mg/5 mg 
ratio 
2.24 2.97  
    
10 mg 0.225  
(0.145 – 0.349) 
0.339 
 (0.0.228– 0.504) 
1.51 (1.27 – 1.78) 
20 mg 0.508  
(0.328 – 0.788) 
1.07  
(0.722 – 1.59) 
2.11 (1.78 – 2.49) 
20 mg/10 mg 
ratio 
2.26 3.16  
    
20 mg 0.51 (0.33 – 0.79) 1.07 (0.72 – 1.59) 2.11 (1.78 – 2.49) 
40 mg 1.34 (0.84 – 2.15) 3.22 (1.9 – 5.2) 2.4 (2.38 – 2.42) 
40 mg/20 mg 
ratio 
2.64 3.01  
 
AUC increases nonlinearly for both intravenous and oral formulations with single and repeated 
dosing as dose increases from 20 to 40 mg, and this increase is higher for oral capsules (Table 2).
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Table 2. AUCs, geometric mean (95% confidence interval), in intravenous and oral formulations of 
esomeprazole. (Adapted from (Andersson, Hassan-Alin, et al., 2001)). 
 AUC (mg·h/L)  
Dose, intravenous Day 1 Day 5 Day 5/ day 
1 ratio 
20 mg 0.922 
(0.746–1.13) 
1.29 
(1.05 – 1.59) 
1.39 
40 mg 2.35 
(1.89 – 2.91) 
4.35 
(3.63 – 5.22) 
1.86 
40 mg/ 20 mg ratio 2.55 3.38  
Dose, oral capsule    
20 mg 0.462 
(0.352-0.611) 
0.881 
(0.670 – 1.160) 
1.90 
(1.72 – 2.09) 
40 mg 1.49 
(1.05 – 2.12) 
3.88 
(2.96 – 5.07) 
2.59 
(2.11 – 3.19) 
40 mg/ 20 mg ratio 3.22 4.39  
 
8.9.5 Effect of food on esomeprazole pharmacokinetics 
Food delays and reduces the bioavailability of esomeprazole. It was observed in a study assessing 
the pharmacokinetics of esomeprazole in fed (dose before 15 min of a meal) versus fasting state 
(dose before 4 h of a meal) that, under fasting conditions, time to maximum concentration (Tmax) 
was faster by half the time compared to Tmax in fed state while peak concentration (Cmax) and AUC 
were higher by ~ 3% and 66%, respectively. This is because esomeprazole is an acid labile drug 
and a delay in gastric emptying exposes it more to the acidic environment of the stomach, leading 
to its degradation. The decrease in Cmax and AUC was greater on single dose than with repeated 
dosing. This could be due to the increase in gastric pH that occurs with repeated dosing of 
esomeprazole, which would reduce its degradation, improving its bioavailability (Sostek, Chen and 
Andersson, 2007). The product label for the capsule formulation of oral esomeprazole recommends 
that esomeprazole be taken without food while that of the MUPS formulation states that it can be 
taken with or without food.
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8.9.6 Effect of sex on esomeprazole pharmacokinetics 
Females have lower body weight than males and are thus expected to have a lower clearance and 
volume of distribution. In addition to differences in body weight, females have a lower activity of 
CYP2C19, which is the major metabolizing enzyme for esomeprazole. Consequently, females are 
expected to have higher AUC and Cmax for esomeprazole. This has been shown to be the case in a 
pooled analysis of data from 12 studies. This analysis showed that in females, esomeprazole AUC 
and Cmax were 30% higher than males on single dose. With repeated dosing, AUC and Cmax in 
females were only 13 to 14% higher and this difference was not statistically significant. The effect 
of sex on the disposition of esomeprazole has been reported to be clinically insignificant for the 
gastric acid inhibitory effects (Andersson et al., 2001). 
8.9.7 Potential effects of pregnancy and preeclampsia on the pharmacokinetics of 
esomeprazole 
Some physiological changes related to pregnancy may affect the pharmacokinetics of 
esomeprazole. Pregnancy is associated with a 23% increase in total body weight, a 32% increase in 
total fat mass, and a 41% increase in total body water by the third trimester (Ke, Rostami-Hodjegan, 
et al., 2014). It is expected that, in pregnancy, increase in gastric emptying time by 30% to 50% 
could cause a lag in absorption, plasma volume expansion by 50% could  increase Vd, and decrease 
in albumin concentration by 20-40% could lead to a larger free fraction and consequently a decrease 
in total plasma drug concentration of esomeprazole (Costantine, 2014). In preeclampsia, increase 
in plasma volume in the third trimester is ~13.3% lower than normal pregnancies which could 
reduce Vd compared to that in normal pregnancies  (de Haas et al., 2017) and albumin concentration 
is further decreased, which could reduce total plasma concentration of esomeprazole even more 
(Gojnic et al., 2004). Additionally, CYP3A4 is upregulated by approximately 2- fold while 
CYP2C19 activity decreases by 68% due to downregulation during the third trimester which is 
mediated by pregnancy related hormones including estrogen, progesterone, placental growth 
hormone, and cortisol (Jeong, 2010; Papageorgiou, Grepper and Unadkat, 2013; Ke, Nallani, et al., 
2014). It is expected that this might change the metabolic pathway in pregnancy and might affect 
first-pass and therefore bioavailability. These changes could affect the overall exposure of 
esomeprazole and influence the outcome of preeclampsia treatment. The pharmacokinetics of 
esomeprazole in early-onset preeclampsia patients will be characterized in this study by using 
nonlinear mixed-effects modelling. 
  
15  
8.10 Nonlinear mixed-effects modelling 
A model is a mathematical description of the phenomenon under study. In the case of population 
pharmacokinetics, a model is used to describe how drug concentration varies over time between 
different individuals in a population. The models used for this are called nonlinear mixed-effect 
models, as their parameters are determined by fixed effects, whose value is common to the whole 
population, and random effects, which vary between individuals or occasions. The model is 
composed of two parts. The first is the structural model, which is a mathematical description of the 
physiological processes of absorption, distribution, and elimination of a drug in the body. The 
second part is the variability or stochastic model, which describes the differences in parameters 
values between individuals and occasions (random effects). Random effects are organised with a 
hierarchical structure consisting of interindividual variability (IIV), which describes random 
variability of the pharmacokinetic parameters of an individual relative to the typical population 
parameters, interoccasion variability (IOV), which describes how these parameters randomly vary 
between different sampling occasions within an individual, and residual unexplained variability 
(RUV), which describes any remaining sources of variability between observations and the model 
predicted values for observations, such as errors in sampling times or assay error. The model 
estimates the variances of the distributions for the random variables describing IIV and RUV in 
addition to the typical pharmacokinetic parameters (Mould and Upton, 2013). Typical parameters 
are estimated in the model taking into account known or identified potential sources of variability, 
called covariates, such as through allometric scaling (i.e. adding body size descriptors such as 
weight, fat mass, or fat-free mass) (Anderson and Holford, 2008, 2009). 
Although the methodology is more complex, population pharmacokinetic modelling offers 
advantages compared to noncompartmental analysis (NCA). NCA is a model-free pharmacokinetic 
analysis method in which secondary pharmacokinetic measures (e.g. AUC, Cmax, Tmax and half-life) 
are directly calculated from each subject’s profile. Population pharmacokinetic models enable 
estimation of typical primary parameters for the population of a study as well as the expected and 
random variability around these parameters while NCA does not consider variability. NCA methods 
require rich data while model-based methods are more forgiving of sparse data, e.g. often seen in 
special populations such as children and pregnant women and can be used to describe complex 
pharmacokinetic processes. The use of a model also allows prediction of new scenarios through 
simulations making it a useful tool for design of dose regimens (Bulitta and G. Holford, 2014; 
Barnett et al., 2020). NCA does have some advantages as a tool of pharmacokinetic data analysis. 
Fewer assumptions are made with NCA, for e.g. there is no assumption made that the underlying 
pharmacokinetic parameters are log normally distributed. When the pharmacokinetic parameter of 
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interest for a drug is overall exposure, such as in bioequivalence studies, or metabolite to parent 
ratios for drugs, NCA can be used adequately since it is a robust method for estimating AUC. 
Additionally, it can be used to compare the performance of a model through comparisons of the 
NCA metrics of simulated pharmacokinetic profiles to that of observed profiles (Acharya et al., 
2016). 
 
9 AIMS AND OBJECTIVES 
9.1 Specific Aims 
The aim of this study is to characterize the pharmacokinetics of esomeprazole in pregnant patients 
with early-onset preeclampsia and compare its pharmacokinetics with that of healthy non-pregnant 
subjects. Additionally, this study aims to predict a dose of esomeprazole to be used for future 
clinical trials involving early-onset preeclampsia patients. 
9.2 Hypothesis 
The pharmacokinetics of esomeprazole are expected to be altered in early-onset preeclampsia 
patients due to pregnancy related physiological and metabolic changes. Changes are expected in 
bioavailability, volume of distribution, and clearance, and this might necessitate dose adjustments 
to achieve the same concentration as in non-pregnant. 
9.3 Objectives 
1. Through population pharmacokinetic modelling, determine the pharmacokinetic parameters 
of esomeprazole in pregnant preeclamptic patients from the PIE trial and compare how they differ 
from those of healthy non-pregnant subjects. 
2. Through comparisons of the exposures of esomeprazole and metabolites between pregnant 
and non-pregnant data, investigate how the metabolism of esomeprazole changes between the two 
groups. 
3. Investigate how esomeprazole exposure in pregnant women with preeclampsia compares 
with drug levels from in vitro preclinical studies that showed a potential effect therapeutic effect. 
4. Use the developed model to predict exposures at higher doses and to investigate if preclinical 




10.1 Study population 
Pharmacokinetic data for pregnant, early-onset preeclampsia patients were obtained from patients 
in the treatment arm of the PIE study. Pregnant women who participated in this study were those 
with single pregnancies diagnosed with early-onset preeclampsia (Cluver et al., 2015, 2018). 
Exclusion criteria included: 
 Maternal or fetal compromise that necessitated delivery within 48 hours 
 Pregnancies with a suspicion of major fetal anomaly or malformation 
 Eclampsia or HELLP syndrome 
 Severe hypertension that could not be controlled within 48 hours of admission 
 Cerebrovascular event 
 Severe renal impairment with creatinine greater than 125 mmol/L 
Patients must not have been using PPIs or medications that could interact with PPIs. They must not 
have had contraindications to the use of PPIs. A comprehensive list of inclusion and exclusion 
criteria can be found in the PIE study protocol (Cluver et al., 2015, 2018). 
Pharmacokinetic data for non-pregnant healthy subjects were obtained from two studies conducted 
by Hunfeld et al. which were similar in study design. One of the studies compared the efficacy of 
esomeprazole versus pantoprazole (eso-panto), while the other study compared the efficacy of 
esomeprazole versus rabeprazole (eso-rabe) in relation to pharmacokinetics and CYP2C19 
polymorphism. These studies were investigator-blind, randomized, two-way cross- over studies. 
Healthy subjects between ages of 18 and 60 were included. Subjects were excluded if they were 
pregnant or lactating, if they had used PPIs during the 14 days prior to day one of the study, if they 
had used antibiotics during the 30 days prior, or if they had any contraindications to the use of PPIs 
(Hunfeld et al., 2010, 2012). Pharmacokinetic data from the two studies of non-pregnant subjects 
were combined into a pooled dataset for the analysis in this study. Only the data from the 
esomeprazole arm was used from the control studies, with the aim of investigating a possible change 




The PIE trial had approval from the South African Medicines Control Council and Health Research 
Ethics Committee. Patients in the trial gave written informed consent (Cluver et al., 2018). Non-
pregnant data for this project was obtained from two studies by Dutch researchers (Hunfeld et al) 
and had approval from the institutional review board of the Haga Teaching Hospital, Netherlands. 
All subjects gave written informed consent (Hunfeld et al., 2010, 2012). For this project, there was 
no need to obtain further ethical approval, since the data received was from clinical trials that had 
received approval as stated above. 
 
Table 3. Summary of study characteristics of pregnant patients with early-onset preeclampsia (Cluver et 
al., 2018) and non-pregnant subjects (Hunfeld et al., 2010, 2012). 
Study Pregnant Non-pregnant 
Formulation Nexium delayed-release capsules Nexium MUPS tablets 
Dose Oral 40 mg Oral 40 mg 
Meal 2 hrs post dose 5 mins post dose 
Sampling Day1: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 
2, 4, 8, 24 hrs 
Day5: pre-dose 
Day1 and day5: 
Pre-dose, 0.5, 0.75, 1, 1.5, 2, 3, 
4, 6, 7, 8 hrs 
LLOQ 
(ESO) 
0.001 mg/L 0.026 mg/L 
BLQ (ESO) 21 61 
LLOQ = lower limit of quantification, BLQ = below lower limit of quantification, ESO 
= esomeprazole 
 
10.2 Pharmacokinetic data 
Patients in the treatment arm of the PIE trial received a 40 mg daily dose of esomeprazole (delayed 
release capsules, Nexium®, Astra Zeneca) in fasted state and meals were given two hours after 
dose. A subgroup of these patients underwent plasma sampling and had samples collected pre-dose 
and post-dose at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, and 24 hours after the first dose. Pre-dose samples 
were taken on day5 after repeated daily dosing. Concentrations of esomeprazole and its metabolites 
(esomeprazole sulfone, 5-hydroxy esomeprazole, and 5-O- desmethyl esomeprazole) were 
quantified using a validated ultra-performance liquid chromatography-tandem mass spectrometry 
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method. The lower limit of quantification (LLOQ) was 0.001 mg/L for all analytes (Cluver et al., 
2015, 2018). 
Participants in the non-pregnant studies received a 40 mg daily dose of esomeprazole (MUPS 
tablets, Nexium®, Astra Zeneca) in fasted state in the morning and meals were given 5 minutes 
after dose. Plasma samples from both studies were collected pre-dose and post-dose at 0.5, 0.75, 1, 
1.5, 2, 3, 4, 6, 7, and 8 hours on day1 of dosing. In the eso-panto study, after repeated daily dosing, 
on day5, samples were collected pre-dose and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-dose. 
Concentrations of esomeprazole and its metabolites (esomeprazole sulfone and 5- hydroxy 
esomeprazole) were quantified by liquid chromatography (HPLC). The LLOQ was 0.026 mg/L for 
all analytes (Hunfeld et al., 2010, 2012). 
10.3 Data analysis overview 
The initial plan was to model the pregnant data together with the data from healthy non- pregnant 
subjects in the same model, in order to capture the differences due to pregnancy by performing a 
test within the model. However, as shown by the profiles in the results section and explained in 
detail in the discussion  section, it was observed during the data exploration that there were 
unexpected large differences in the absorption of esomeprazole between the two datasets. These 
seemed unlikely to be caused by pregnancy, but rather due to other differences between the 
studies. The erratic absorption in the healthy volunteers’ dataset is very difficult to describe in a 
model and it was decided to only model the pregnancy data of esomeprazole and use AUC results 
(for both esomeprazole and its metabolites) from a non-compartmental analysis for the 
comparison with the healthy volunteer’s data.
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10.4 Population pharmacokinetic modelling 
A population pharmacokinetic model describing esomeprazole disposition was developed in early-
onset preeclamptic pregnant patients. Estimation of parameter values was performed initially with 
Monolix (version 2019R2, Lixoft®) and the stochastic approximation expectation maximization 
(SAEM) algorithm. The software NONMEM (version 7.4.2, Icon®) and the algorithm first-order 
conditional estimation with interaction (FOCE-I) were subsequently used to estimate parameter 
values, and these were compared with those from Monolix. R (version 4.0.2) was used for data 
exploration, statistical and graphical analysis, and model diagnostics. 
For the population pharmacokinetic model, only pregnant esomeprazole data was used. Pre- dose 
concentrations, which were used to confirm that the patient had not recently taken esomeprazole 
and were below the limit of quantification (BLQ), were excluded from the analysis. In Monolix, the 
M3 method was used whereby the maximum likelihood estimation method is used to fit the model 
to the observations and for the BLQ values the likelihood that these observations are BLQ is used 
(Beal, 2001). In NONMEM, the post-dose observations that were BLQ were censored and handled 
as follows: LLOQ/2 was imputed to the first BLQ value and its additive error was inflated by 
LLOQ/2 to mitigate the effect of the imputation, then the trailing BLQ values were excluded from 
the model fit. This is similar to the M6 method. To screen outliers, observations that resulted in 
unreasonably high residual error in the model were identified by means of goodness-of-fit (GOF) 
plots and were ignored. 
Several structural models were tested to describe the pharmacokinetics of esomeprazole. One- or 
two-compartment disposition with first-order elimination, and first-order absorption, either with no 
delay, a lag time, and transit absorption compartment. A log-normal distribution was assumed for 
the IIVs and the RUV was described using a combined additive and proportional error model. The 
typical value of relative bioavailability was fixed to 1.
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Allometric scaling was applied to apparent clearance (CL/F) and apparent volume of distribution 
(Vd/F) to account for differences in body size between individuals according to the formula below 
(Anderson and Holford, 2008, 2009). Pi and Pp are the individual and typical CL/F or Vd/F 
respectively, while Cov represents the covariates tested, which were weight and fat-free mass, and 
z is the allometric scaling value which was fixed (0.75 for CL/F and 1 for Vd/F). 
 





            (𝑒𝑞. 1) 
 
Model selection was based on changes in the objective function value or -2 log likelihood (OFV or 
-2LL); convergence success of the run; precision of the parameter estimates (relative standard 
errors, %RSEs); inspection of diagnostic plots such as standard GOF plots, visual predictive checks 
(VPC); and biological plausibility of the parameter estimates. A VPC plot of the final model was 
obtained by simulating 500 datasets and plotting the 5th, 50th, and 95th percentiles of the simulated 




10.5 Metabolite to parent AUC ratios (AUCm/AUCp) 
To investigate possible changes in the metabolic pathways of esomeprazole, the AUCs of 
esomeprazole, 5-hydroxy esomeprazole, and esomeprazole sulphone were determined using 
Pkanalix (version 2019R2, Lixoft®) and metabolite to parent AUC ratios were calculated. These 
values were calculated for the pregnant women day1 data, and non-pregnant adults on day1 and 
day5 using molar concentrations (micromol·h/L) to correct for differences in molecular weight. 
AUC ratios of 5-hydroxy esomeprazole to esomeprazole (AUChyd/AUCeso) comparisons were used 
to investigate changes in the CYP2C19 pathway while AUC ratios of esomeprazole sulphone to 
esomeprazole (AUCsulf/AUCeso) for changes in the CYP3A4 pathway. These values were calculated 
for pregnant women on day1 of treatment and compared with non-pregnant data on day1 to show 
the effect of pregnancy. Comparisons of pregnant day1 with non-pregnant day5 or non-pregnant 
day1 with non-pregnant day5 were preformed to show the effect of autoinhibition with repeated 
dosing. The Mann-Whitney-Wilcoxon test was used to perform these comparisons at a significance 
level of 0.05. For the overall analysis data, the impact of weight and age on AUC was assessed by 
linear regression analysis of log transformed AUCs. R was used for the regression analysis, 
statistical comparisons, and plotting of results. 
For the calculation of AUC, data of all analytes, i.e. esomeprazole, 5-hydroxy esomeprazole, and 
esomeprazole sulphone, from both pregnant and non-pregnant studies were used. 
Day1 data (i.e. single dose data of pregnant patients and of non-pregnant subjects) was handled as 
follows: 
 Pre-dose observations were BLQ and were set to 0. 
 Post-dose BLQ observations were assumed as 0 if before Tmax and imputed LLOQ/2 if after 
Tmax (Pkanalix-NCA, 2019). 
 AUC0-inf was calculated using log-linear extrapolation to infinity. The extrapolation was 
performed only if the last concentration (Clast) was not BLQ and the area after Clast was 
calculated as Clast/λz, where λz is the terminal slope of the log concentration versus time 
profile. Profiles for which the terminal half- life could not be estimated were excluded by 
the software. If Clast was BLQ, no extrapolation was performed and AUClast was used.  
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Day5 data (i.e. steady state data of non-pregnant subjects) were handled as follows: 
 There were no BLQ observations. 
 AUC0-24 were calculated using the linear up log down method. Since the non-pregnant 
sampling schedule was up to 8 hours, a 24-hour sample was included in the day5 dataset of 
the non-pregnant subjects and assumed to have same concentrations as the pre-dose samples. 
10.6 Translation from in vitro to in vivo target 
To determine a target concentration to achieve in preeclampsia patients, some considerations had 
to be made to translate the preclinical concentrations to concentrations in patients. The in vitro target 
esomeprazole concentration of 50 µM (17.3 mg/L) was chosen based on the preclinical study by 
Onda et al. This was the lowest concentration amongst those tested at which a significant difference 
from control was observed for the biomarker lowering effect of esomeprazole in the in vitro studies 
(middle bar for esomeprazole in Figure 2). 
Only unbound drug is expected to interact with the target and be pharmacologically active, so the 
expected protein binding difference between in the in vitro preclinical experiments and the clinical 
levels in pregnant women has to be considered. 
Esomeprazole is 97% protein bound to human serum albumin (HSA) (Andersson, Röhss, et al., 
2001; Rabbani and Ahn, 2019). The fraction unbound (fu) in the in vitro culture, in which fetal calf 
serum was assumed to be the only source of bovine serum albumin (BSA), needed to be calculated. 
Equation 2 was used to calculate fu (Schalkwijk, Greupink and Burger, 2017) where Kd is the 





                             (𝑒𝑞. 2) 
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A concentration of 16 g/L was used for the protein content of the culture based on information from 
the Sigma Aldrich certificate of analysis for fetal calf serum used in the preclinical study. 
Esomeprazole binds one-to-one with albumin, thus Bmax for esomeprazole in the culture was taken 
as 16 g/L. The Sigma Aldrich information also provided the molecular weight of BSA as 66430.3 
g/mol. The Kd value for BSA to esomeprazole could not be obtained from literature, but a value 
could be found for Kd for BSA to omeprazole at temperature of 35°C: 13.5 µM (Deepa, Kabir and 
Amran, 2016). Since esomeprazole has been reported to have a Kd value for HSA similar to 
omeprazole (Pawar et al., 2017), it was assumed that the use of omeprazole Kd for BSA would 
suffice for this rough estimation. 
10.7 Unbound in vitro esomeprazole AUC over 24 hours incubation 
Esomeprazole is not stable in plasma. Its degradation half-life during the in vitro incubation was 
assumed to be 8 hours based on stability information on esomeprazole product label (Nexium 40 
mg label) at the same temperature and pH as in the in vitro culture. 
To calculate exposure of unbound esomeprazole over the 24 hours of in vitro incubation (fAUC0-
24) and adjusting for the degradation, the following steps were taken: 
The degradation rate constant, k, was derived from the degradation half-life using equation 3 (t1/2 = 
8 hours). 
            𝐾 = ln(2) /𝑡1
2
                                            (𝑒𝑞. 3)          
The unbound starting concentration, C0, was calculated using equation 4. 
𝐶0 = 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 × 𝑓𝑢       (𝑒𝑞. 4) 
 
Equation 5 was used to calculate the concentration after 24 hours, C24. 
                                           𝐶𝑡 = 𝐶0  · 𝑒
−𝑘·𝑡  𝑤𝑖𝑡ℎ (𝑡 = 24 ℎ)             (𝑒𝑞. 5) 
AUC of esomeprazole in the incubation was calculated using equation 6. This formula is valid for 
exponential degradation/decay. 
 
𝑓𝐴𝑈𝐶0−24 = (𝐶0 − 𝐶24)/𝐾                           (𝑒𝑞. 6)
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These calculations provided an equivalent AUC level to target in patients. The preclinical target 
to be compared with exposure in pregnant patients is going to be either the instantaneous 
concentration as Cmax or the 24-hour exposure as AUC, i.e. the calculated fAUC0-24.
10.8 Unbound in vitro esomeprazole Cmax 
The lowest esomeprazole concentration which was found to have effect in the in vitro incubation, 
i.e. 50 µM or 17.3 mg/L, was taken for comparison with Cmax of the pregnant patients. This was 
adjusted for protein binding by multiplying with the fraction unbound (fu) calculated from equation 
2. 
10.9 Unbound pregnant esomeprazole AUC 
The preclinical unbound AUC during the time of incubation, i.e. fAUC0-24, was compared to the 
median fAUC0-24 for a single dose in the pregnant patients, or the simulated AUC0-24 at steady-state. 
To calculate the unbound AUC of the pregnant data from the PIE study (fAUC0- 24), the median 
AUC0-24 was multiplied by the estimated fu in pregnancy. In non-pregnant healthy subjects, albumin 
binding of esomeprazole is 97%, however Plasma albumin concentrations are lowered by ~31% in 
the third trimester (Ke, Rostami-Hodjegan, et al., 2014) and are expected to be in the range of 25 
to 35 g/L. In preeclampsia, concentrations below 30 g/L have been observed (Gojnic M, Petkovic 
S, Papic M, 2004). Among reports for plasma albumin concentration during the third trimester in 
preeclampsia are (mean ± standard deviation) 25.5 ± 2.8 g/L (Benoit and Rey, 2011) and (mean ± 
SEM) 26.79 ± 4.68 (Dai et al., 2017). 
Assuming average plasma albumin concentration, of 25 g/L in pregnant early-onset preeclampsia 
patients, fu was estimated using equation 2. Esomeprazole binds one-to-one with albumin, thus 
Bmax was taken as 25 g/L. A molecular weight of HSA of 66000 g/mol and Kd value for HSA to 
esomeprazole of 20 µM were used (Pawar et al., 2017). 
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10.10 Simulations 
Simulations were performed using the model developed for pregnant patients with early-onset 
preeclampsia to predict exposures for higher doses of esomeprazole in these group of patients with 
single and repeated dosing. Three scenarios were simulated to investigate exposures for the highest 
dose of esomeprazole which has been reported to be used clinically, i.e. 120 mg BID (McKeage et 
al., 2008). Two main assumptions needed to be made for these simulations: 
(i) the dose exposure increase for higher doses of esomeprazole, and (ii) the increase in 
exposure from single dose to steady state. 
The scenarios simulated were as follows: 
• Scenario one assumed (i) linear (or dose proportional) increase in AUC with dose 
escalation and (ii) no change in AUC with repeated dosing. 
• Scenario two assumed (i) maximum increase in AUC with dose escalation and (ii) 
maximum increase in AUC with repeated dosing. 
• Scenario three was a compromise between the first two scenarios and possibly a best 
guess estimation of exposures for pregnant patients. 
 
11 RESULTS 
11.1 Pharmacokinetic data 
From the treatment arm of the clinical trial involving pregnant patients with early-onset 
preeclampsia, i.e. the PIE trial, 10 patients who underwent pharmacokinetic sampling were included 
in this analysis. From the healthy volunteer eso-panto and eso-rabe studies by Hunfeld et al., a 
pooled dataset contributed 26 subjects. The non-pregnant group included participants of both sexes, 
65% of whom were female. The median weight of pregnant patients was 98.8 kg and that of non-




The pregnant data consisted of 96 observations of esomeprazole. All pre-dose observations and 
~13% of post-dose observations were BLQ. During modelling, 10% of post-dose observations were 
identified as outliers by means of GOF plots, resulting in unreasonably high residual error in the 
model, and were subsequently ignored. 
The non-pregnant data consisted of 266 day1 observations for the 26 subjects. For 19 of these 
subjects, day5 samples were also available, consisting of 135 observations. All pre-dose 
observations and ~13% of post-dose observations were below the limit of quantification.  
 
Table 4. Summary of subject characteristics of pregnant patients (Cluver et al., 2018) and non- pregnant 
healthy subjects (Hunfeld et al., 2010, 2012). 
Parameter Pregnant (Cluver et al.) 
(n = 10) 
Non-pregnant (Hunfeld et al.) 
(n = 26) 
Age, years, median 
(range) 
30 (21-43) 21 (18-27) 
Weight, kg, median 
(range) 
98.8 (56-126) 69 (54-89) 
BMI, kg/m2, median 
(range) 
37.6 (21.6-47.9) 21.4 (18.3-27.5) 
Gestational age, 
weeks, median (range) 
29 (26-31) - 
No. of males (%) 
























HetEM = heterozygous Extensive Metabolizer 
HomEM = Homozygous Extensive Metabolizer 
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11.2 Exploratory data analysis 
Day1 pharmacokinetic profiles of esomeprazole and its metabolites, esomeprazole sulfone and 5-
hydroxy esomeprazole, from the pregnant group are presented in Figure 5. In the pregnant patients, 
absorption is fast with peak concentrations around 2 hours. The profiles are regular, although some 
double peaks during absorption can be seen for patients 4 and 5. Unexpected high concentrations 
of esomeprazole and its metabolites could be observed at the last sampling time point for patient 8 
and only for the hydroxy metabolite for patient 6. Concentrations for esomeprazole are mostly larger 
than that of its metabolites, except for patient 6 and patient 10, in whom esomeprazole sulfone peak 




Figure 5. Concentration-time day1 profiles of pregnant patients with early-onset preeclampsia. Red, green, 
and blue profiles are of esomeprazole, and its hydroxy and sulfone metabolites, respectively. 
Day1 pharmacokinetic profiles of esomeprazole and its metabolites, esomeprazole sulfone and 5-
hydroxy esomeprazole, from the non-pregnant group are presented in Figure 6. Absorption is much 
slower in these profiles, with some subjects seemingly having no absorption for up to 3 to 4 hours 




Figure 6. Concentration-time day1 profiles of healthy, non-pregnant subjects. Red, green, and blue profiles 
are of esomeprazole, and its hydroxy and sulfone metabolites respectively. Observations that are below the 
limit of quantification are plotted as half the lower limit of quantification.  
On day5, as shown in Figure 7, double peaks are not seen for profiles from the same subjects 
shown in Figure 6. 
 
Figure 7. Concentration-time day5 profiles of healthy, non-pregnant subjects. Red, green, and blue profiles 
are of esomeprazole, and its hydroxy and sulfone metabolites respectively. Observations that are below the 
limit of quantification are plotted as half the lower limit of quantification. 
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11.3 Model description 
Day1 esomeprazole data of the pregnant patients was best described by a one compartment 
disposition model with first-order elimination and transit absorption compartments. A schematic of 




Testing the inclusion of a second compartment did not improve the model. There was an 
improvement of the OFV with transit absorption compartment model (a decrease in OFV of 7.5 
points compared to lag absorption (P-value < 0.05)). The number of transit compartments (NN) was 
estimated to a large number and was fixed to 50 (without resulting in significant worsening of fit) 
to make the parameter estimates more stable (Savic et al., 2007). Adding allometric scaling as 
weight on apparent clearance and volume of distribution improved the OFV by 10.5 points 
compared to no scaling. Using fat-free mass as an alternative descriptor of body size did not improve 
the fit. The results of parameter estimates from NONMEM were compatible with those from 
Monolix. The final model parameter estimates in the model are presented in Table 5. 
Figure 8. Schematic of esomeprazole model in pregnant patients with early-onset preeclampsia. 
MTT= mean transit time, NN = number of transit compartments, Ktr = transfer rate between 
transit compartments, Ka = absorption rate constant, CL/F = apparent clearance. 
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Table 5. Parameter estimates of esomeprazole model for pregnant patients with early-onset preeclampsia. 
Description Unit Typical value (95% CI)
a
 RSE% 
Absorption rate constant h-1 1.54 (0.486-10.4) 54 
Clearanceb L/h 19.2 (14.2-26.0) 15 
Volume of distributionb L 44.2 (29.9-56.6) 13 
Bioavailability - 1 FIXED - 
Number of transit 
compartments 
- 50 FIXED - 
Absorption mean transit 
time 
h 0.503 (0.378-0.668) 13 
Inter individual 
variability 
   
KA (%CV)c % 269.2 (87.6-2389.5) 29 
CL (%CV)c % 41.2 (12.4-58.4) 32 
MTT (%CV)c % 37.3 (13.4-56.9) 30.1 
Residual error    
Proportional error % 34.2 (24.8-41.1) 14 
Additive error mg/L 0.015 (0.00158-0.0337) 39 
a95% confidence intervals (CI) were obtained by bootstrap (n=1000) 
bAllometric scaling was used for clearance and volume of distribution (by weight); the 
typical values reported are for the median weight of 98.8 kg as reported in Table 4. 
cIIVs were assumed to be log-normally distributed and are reported as approximate 
%CVs. 
 
11.4 Model Evaluation 
GOF plots for the final model are shown in Figure 9. There is no apparent pattern for the conditional 
weighted residual versus time and conditional weighted residual versus population predictions and 
points are scattered around the line of unity for the observed versus population predicted values as 
well as observed versus individual predicted values. These plots do not highlight any 
misspecification in the model. A VPC for the final model is shown in Figure 10, showing that the 
5th, 50th, and 95th percentiles of the data agree with the 95% confidence interval of the simulations 
for each percentile. 
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Figure 9. Goodness-of-fit plots for final model. DV = observations, IPRED = individual predictions, PRED 
= population predictions, CWRES = conditional weighted residuals. Grey line is line of identity and blue 
line is a smooth line to indicate general trend. 
 
 
Figure 10. Visual predictive check for final model. Blue dots are observations, red lines are 5th, 
50th, and 95th percentiles for the observations, and shaded areas are respective simulated 95% 
confidence intervals for each percentile. Yellow ticks at the bottom indicate bins. 
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11.5 Exposure comparisons between pregnant and non-pregnant 
A comparison of the AUCs between pregnant and non-pregnant was performed to get some insight 
into how the metabolic pathways may change due to pregnancy (day1 pregnant and non-pregnant 
comparisons) and autoinhibition (day1 pregnant and day 5 non-pregnant comparisons). Table 6 
shows AUC values for esomeprazole and AUCm/AUCp values for pregnant and non-pregnant. 
Profiles for which the terminal half-life could not be calculated were excluded by the software and 
thus some comparisons had fewer profiles. Due to these exclusions, the sub-optimal sampling 
schedule and other differences between the studies, we did not aim for this comparison of AUC 
values to be a fully quantitative analysis, but rather as an opportunity to get a glance at the trends 
in how exposure differs and identify possible metabolic pathway changes between pregnant and 
non-pregnant.  
 
Table 6. Exposure and metabolite to parent exposure ratio comparisons between pregnant patients (Cluver 
et al) and non-pregnant subjects (Hunfeld et al). Number of profiles included in each study are shown 
below each value. 




Pregnant day1 2.52 0.0543 2.00 
 (1.85-3.05) (0.0500-0.0914) (1.35-2.61) 
No of subjects 7 7 7 
Non-pregnant 1.94 0.188 0.700 
day1 (1.50-3.02) (0.156-0.227) (0.636-1.00) 
No of subjects 20 14 14 
Non-pregnant 6.25 0.0777 1.18 
day5 (4.38-8.69) (0.0569-0.108) (0.981-1.58) 
No of subjects 17 17 17 
AUCeso = esomeprazole exposure, AUChyd/AUCeso = 5-hydroxy esomeprazole to 
esomeprazole ratio, AUCsulf/AUCeso = esomeprazole sulphone to esomeprazole 
ratio 
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Day5 esomeprazole AUC of non-pregnant subjects was significantly larger (p-value < 0.05) than 
the esomeprazole AUC of both day1 pregnant patients and day1 non-pregnant subjects. Day1 
esomeprazole AUC of pregnant patients was not significantly different from that of day1 non-
pregnant subjects (p-value > 0.05) (Figure 11). The AUC comparisons were adjusted for weight (r 
= -0.197, p-value > 0.05) and age (r = -0.138, p-value > 0.05) through linear regression analysis and 





Figure 11. Esomeprazole AUC stratified by pregnant day1 (blue box), non-pregnant day1 (yellow 
box), and non-pregnant day5 (grey box). The dots represent individual values. Whiskers show the 
2.5th and 97.5th percentiles. 
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Day1 AUChyd/AUCeso of non-pregnant subjects was significantly larger (p-value < 0.05) than those 
of both day1 pregnant patients and day5 non-pregnant subjects. Day1 AUChyd/AUCeso of pregnant 
subjects was not significantly different (p-value > 0.05) from that of day5 non- pregnant subjects 
(Figure 12). 
 
Figure 12. Ratio of 5-hydroxy esomeprazole to esomeprazole AUC (AUChyd/AUCeso) stratified by pregnant 
day1 (blue box), non-pregnant day1 (yellow box), and non-pregnant day5 (grey box). The dots represent 
individual values. Whiskers show the 2.5th and 97.5th percentiles. 
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Day1 AUCsulf/AUCeso of pregnant patients was significantly larger (p-value < 0.05) than those 
of both day1 non-pregnant and day5 non-pregnant subjects. Day5 AUCsulf/AUCeso of non- 
pregnant subjects was significantly larger (p-value < 0.05) than those of day1 non-pregnant 




11.6 Cmax and AUC comparisons between preclinical in vitro and in vivo pregnant 
studies 
The lowest preclinical concentration found to be effective for lowering sFlt-1 and sEng was 
17.3 mg/L, and this was taken as the preclinical target for this study. When adjusted for protein 
binding (fu = ~5.3%), the unbound preclinical effective concentration is 0.917 mg/L. From this, 
unbound esomeprazole AUC (fAUC0-24) in the preclinical study was calculated to be 9.29 mg·h/L. 
Median Cmax on day1 in the pregnant women was 0.695 mg/L. When adjusted for protein binding 
in pregnancy (fu = ~ 5.02%), the unbound median Cmax in the pregnant patients is 0.0349 mg/L. The 
preclinical unbound concentration of 0.917 mg/L is more than 25-fold higher than the unbound Cmax 
in pregnant. 
 
Figure 13. Ratio of esomeprazole sulphone to esomeprazole AUC (AUCsulf/AUCeso) stratified 
by pregnant day1 (blue box), non-pregnant day1 (yellow box), and non-pregnant day5 (grey 
box). The dots represent individual values. Whiskers show the 2.5th and 97.5th percentiles. 
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Median AUC (AUC0-24) observed on day1 in the pregnant women study was 2.52 mg·h/L. 
Assuming the binding to be 5.02%, this gives unbound esomeprazole AUC (fAUC0-24) of 0.127 
mg·h/L. Preclinical target fAUC0-24 (9.29 mg·h/L) is more than 70-fold higher than the fAUC0- 24 
(0.053 mg·h/L) achieved with 40 mg dose of esomeprazole in pregnant patients. 
The above median AUC0-24 for the pregnant patients was the AUC on day1, but on day5 the value 
may be larger due to possible auto-inhibition. To compare the expected exposure in pregnancy on 
day5, or with increasing doses of esomeprazole, simulations were used. 
11.7 Simulation results 
Simulations were performed for an 86-kg pregnant patient which was considered a representing 
typical weight for preeclampsia patients. 
• Scenario one followed (i) dose proportional increase in AUC with dose escalation and 
(ii) no change in AUC with repeated dosing. 
• For scenario two, values to represent maximum increase of AUC were obtained from 
oral esomeprazole literature data of non-pregnant subjects given in Table 2 and were 
put as an effect on bioavailability (Andersson, Hassan-Alin, et al., 2001). The value 
used to depict (i) maximum increase in AUC with dose escalation was 1.61 and the 
value used to depict (ii) maximum increase in AUC with repeated dosing was 2.59. 
• For scenario three, values to represent increase of AUC were obtained from intravenous 
esomeprazole literature data of non-pregnant subjects given in Table 2 (Andersson, 
Hassan-Alin, et al., 2001). These values were put as an effect on bioavailability. The 
value used to depict (i) AUC increase with dose escalation was 1.3 and the value used 
to depict (ii) AUC increase with repeated dosing was 1.86. 
 
The simulations results are shown in Table 7 and depicted in Figure 14.
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Table 7. Simulation results for dose escalation and repeated dosing of esomeprazole based on model 
developed for patients with early-onset preeclampsia. 
 Day 1 Steady state 





    mg/L 
Scenario one – linear dose effect and no auto-inhibition 
40 mg OD 2.31 (0.116) 2.31 (0.116) 0.625 (0.0314) 
40 mg BID 4.62 (0.232) 4.62 (0.232) 0.629 (0.0316) 
80 mg OD 4.62 (0.232) 4.62 (0.232) 1.25 (0.0628) 
80 mg BID 9.21 (0.462) 9.25 (0.464) 1.26 (0.0633) 
120 mg OD 6.94 (0.348) 6.94 (0.348) 1.87 (0.0939) 
120 mg BID 13.82 (0.694) 13.87 (0.696) 1.89 (0.0949) 
Scenario two – maximum effect on dose and on auto-inhibition 
40 mg OD 2.31 (0.116) 5.99 (0.301) 1.62 (0.0813) 
40 mg BID 4.62 (0.232) 11.98 (0.601) 1.63 (0.0818) 
80 mg OD 7.44 (0.373) 19.42 (0.975) 5.25 (0.264) 
80 mg BID 14.83 (0.744) 38.84 (1.95) 5.28 (0.265) 
120 mg OD 11.17 (0.561) 29.13 (1.46) 7.87 (0.395) 
120 mg BID 22.24 (1.12) 58.26 (2.92) 7.92 (0.398) 
Scenario three – intermediate effect on dose and on auto-inhibition 
40 mg OD 2.31 (0.116) 4.3 (0.216) 1.16 (0.0582) 
40 mg BID 4.62 (0.232) 8.59 (0.431) 1.17 (0.0587) 
80 mg OD 6.01 (0.302) 11.19 (0.562) 3.02 (0.152) 
80 mg BID 11.97 (0.601) 22.38 (1.12) 3.04 (0.153) 
120 mg OD 9.02 (0.453) 16.78 (0.842) 4.54 (0.228) 
120 mg BID 17.96 (0.902) 33.57 (1.69) 4.56 (0.229) 
OD = once a day, BID = twice a day, Cmax = total Cmax, fCmax = unbound Cmax, 
AUC0-24 = total AUC, fAUC0-24 = unbound AUC 
Simulated fAUC0-24 is compared to preclinical fAUC0-24 of 9.29 mg·h/L and simulated 
fCmax to preclinical fCmax of 0.917 mg/L 
 
A dose of 120 mg BID is expected to achieve Cmax (total concentration) at steady-state of 1.89, 
7.92, and 4.56 mg/L for scenario one, two, and three, respectively, while the expected steady- 
state AUC is 13.87, 58.26, and 33.57 mg·h/L for scenario one, two, and three, respectively. 
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Figure 14. Results for the three scenarios simulated with single and repeated dosing of esomeprazole at 40 
mg daily (left, first dose scenario one is based on observed values in patients) and 120 mg twice daily 
(right, based on simulations) dose. OD = once a day, BID = twice a day. 
 
After adjusting for protein binding in pregnant patients (5.02%), the 120 mg BID simulation values 
can be compared to the preclinical targets. 
If the pharmacokinetic target is Cmax, which assumes that achieving the in vitro concentrations even 
if for a short time is enough to produce the observed effect, an effective unbound concentration of 
0.917 mg/L must be achieved (derived from the preclinical target concentration of 17.3 mg/L or 50 
µM and adjusting for protein binding). The predicted steady state Cmax values at the highest dose 
were short of the target, i.e. 0.0949, 0.398, 0.229 mg/L for scenario one, two, and three, respectively.  
When targeting a fAUC0-24 value of 9.29 mg·h/L in the preclinical study, the fAUC0-24 values 
predicted at steady state with the simulations were also much lower, i.e. 0.696, 2.92, and 1.69 
mg·h/L for scenario one, two, and three, respectively. 
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The predicted exposures at 120 mg BID are much below the putative targets. Assuming Cmax is the 
pharmacokinetic target, to achieve preclinical effective unbound concentrations of 0.917 mg/L 
(derived from the target concentration of 17.3 mg/L or 50 µM), a dose of approximately 500 mg 
BID would be required. If AUC is assumed to be the pharmacokinetic target, doses higher than 500 
mg BID would be needed to achieve the target preclinical fAUC0-24. Such high doses have not been 
used clinically before and may be unsafe. 
 
12 DISCUSSION 
12.1 Population pharmacokinetic model 
The population pharmacokinetic characteristics of esomeprazole were described in patients with 
early-onset preeclampsia. The population pharmacokinetic model  reported CL/F and Vd/F of 19.2 
L/h and 44.2 L, respectively. These values are greater than values from other population 
pharmacokinetic models of single dose 40 mg oral esomeprazole in non-pregnant: 8.66 L/h and 18.7 
L in patients with gastroesophageal reflux disease (J. Li, T. Lind, 2005), ~7.5 L/h and ~16 L in 
healthy subjects (Nagase et al., 2020), and 9.61 L/h and 9.42 L in healthy subjects (Hunfeld et al., 
2010). This increase in both CL/F and Vd/F could be due to lower bioavailability in pregnant 
patients. The larger Vd/F in our model could also be due to lower plasma protein binding since 
albumin levels decrease by 31% at the final trimester of pregnancy (Ke, Rostami-Hodjegan, et al., 
2014). This could possibly increase distribution to tissues. Higher Vd, ~27 L, has been previously 
reported for intensive care patients with hypoalbuminemia after single 40 mg intravenous 
esomeprazole, compared to ~16 L in healthy subjects (Wilder-Smith et al., 2005), which further 
supports this assumption (Tian et al., 2018). 
Our model shows large interindividual variability during absorption, which is consistent with 
another report (Nagase et al., 2020). This could be due to the interindividual differences in gastric 
pH. Most of the day1 non-pregnant profiles showed multiple peaks in the absorption phase, but not 
all subjects did. The double peaks could be due to mealtimes for these subjects, which were given 
five minutes post dose, or due to the MUPS formulation used. The label of the 40 mg esomeprazole 
MUPS formulation claims that it can be taken with or without food, and indeed, once the drug was 
absorbed, concentrations in line with that in the PIE study were achieved. However, the onset of 
absorption seems to be very erratic when the drug is given shortly before a meal. This is 
physiologically plausible, since there could be an initial fast release in the stomach and absorption 
from the small intestine of a fraction of the dose, followed by a slower release of the remaining 
fraction due to the presence of food. Some of the pellets might be coated with food contents and 
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transit to the small intestine more slowly. Day5 non- pregnant profiles showed no double peaks 
during the absorption phase despite the same mealtimes on day5 as on day1. This could be because 
esomeprazole increases pH in the gastric environment, and this might facilitate faster release in the 
stomach and thereby dissolution and absorption from the small intestine. 
12.2 Comparison of AUCm/AUCp between pregnant and non-pregnant 
The model developed describes the pharmacokinetics of esomeprazole in pregnant patients with 
preeclampsia on the first day of dosing, and the expected effect of auto-inhibition on clearance 
needs to be accounted for to predict steady-state exposures. Data on steady-state exposures in 
pregnancy was not available, but it is known from literature that the changes in esomeprazole 
pharmacokinetics with repeated dosing are due to changes in metabolism (Andersson, Hassan-Alin, 
et al., 2001). Therefore, metabolite to parent AUC ratios, for which we had results both in pregnant 
and non-pregnant subjects, were compared to infer what happens to the metabolism of esomeprazole 
in pregnancy and with repeated dosing. 
In non-pregnant subjects, CYP2C19 activity decreases from day1 to day5 due to autoinhibition 
(Andersson, Hassan-Alin, et al., 2001), therefore the similarities between day1 pregnant and day5 
non-pregnant AUChyd/AUCeso ratios could be indicating a downregulation of CYP2C19 in 
pregnancy. Day1 AUCsulf/AUCeso ratios of pregnant patients were significantly higher than both 
day1 and day5 ratios of non-pregnant subjects which could be explained by an upregulation of 
CYP3A4 as well as a downregulation of CYP2C19 in pregnancy. This is in line with what is known 
in literature about upregulation of CYP3A4 in pregnancy (Isoherranen  and Thummel, 2013; 
Papageorgiou, Grepper and Unadkat, 2013) and could be indicative that metabolism in pregnancy 
shifts dominantly to the CYP3A4 pathway. This shift in the metabolic pathway of esomeprazole to 
CYP3A4 in pregnancy might not significantly affect clearance because, even if CYP3A4 increases, 
CYP2C19, which at lower doses is responsible for most of the clearance, is downregulated. The 
upregulation of CYP3A4 in pregnancy may also decrease bioavailability since CYP3A4 is 
dominantly present in the gut. This could explain the model-reported higher values for CL/F and 
Vd/F in the pregnant patients. The complex interplay between changes in bioavailability and 
metabolism in pregnancy could be the reason why clearance appears higher in pregnancy while the 
AUC between pregnant and non-pregnant subjects on single dosing is similar.
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12.3 Dose escalation and repeated dosing in pregnant patients 
Based on the results of the AUCm/AUCp comparisons, one can speculate about the 
pharmacokinetics of esomeprazole in pregnancy. In non-pregnant, there is more than dose 
proportional increase in AUC with increasing doses, indicating a saturation of clearance and/or first-
pass metabolism. Since the Km of esomeprazole for CYP2C19 is much lower compared to that of 
CYP3A4, it can be surmised that CYP2C19 is the metabolic pathway that gets saturated (Andersson, 
Hassan-Alin, et al., 2001). In pregnancy, CYP2C19 is downregulated and is expected to play a 
smaller role in metabolism of esomeprazole (Ke, Nallani, et al., 2014). Therefore, the nonlinear 
increase in AUC with increasing doses in pregnant is expected to be less pronounced than in non-
pregnant since the nonlinear increase is due to saturation of CYP2C19. 
The increase in AUC with repeated dosing in pregnancy is not expected to be as significant as in 
non-pregnant since the increase is due to autoinhibition of CYP2C19. 
12.4 Simulations 
Out of the three scenarios, scenario three best describes the changes with dose escalation and with 
repeated dosing in pregnancy. The similarity of AUC between 40 mg IV and 40 mg oral 
formulations on repeated dosing could be indicating that with oral capsules at 40 mg repeated dosing 
saturation of first-pass metabolism is nearly achieved. This indicates that the values used to depict 
exposure increase with dose escalation and to depict exposure increase with repeated dosing could 
be overestimating the exposures when used for doses higher than 40 mg. However, even with this 
overestimation, simulations for the highest dose used clinically, i.e. 120 mg BID, showed that the 
preclinical target concentration would not be achieved with this dose in pregnant patients and quite 
high doses would be required to reach the preclinical fAUC0-24 or Cmax. 
12.5 Limitations 
Our study suffers from a number of limitations. It was not possible to jointly model the pregnant 
and non-pregnant data, as initially planned, due to the erratic absorption in the non-pregnant study, 
likely caused by food intake shortly after esomeprazole dose. The large variability in absorption 
and double peaks, which are quite complicated to model, would have made it difficult to then 
separate the effect of food from that of pregnancy on bioavailability.
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Still, the AUC from the non-pregnant studies can be used for comparisons with pregnant since 
exposures and concentrations achieved are similar on day1. Therefore, metabolite to parent AUC 
ratios were compared to investigate and confirm the potential changes in activities of CYP2C19 and 
CYP3A4 during pregnancy. The Mann-Whitney-Wilcoxon test was used for all AUCm/AUCp 
comparisons, although day1 and day5 non-pregnant data had some common subjects. This test has 
less power than a paired statistical test, but significant differences between day1 and day5 non-
pregnant esomeprazole AUCs were detected nonetheless, indicating this did not negatively affect 
the analysis. The sampling schedule for the non-pregnant studies was up to 8 hours which was not 
optimal, but a 24-hour sample was included into the datasets with pre-dose concentrations since it 
is known that esomeprazole concentrations decrease and are undetectable by 24 hours. During the 
AUC calculations, pharmacokinetic profiles for which the terminal phase could not be calculated 
were excluded by the software. This could have introduced bias in the AUC analysis; however, 
these AUCm/AUCp comparisons were not meant to be rigorously quantitative but were rather used 
to  understand trends in the effect of pregnancy and inhibition with repeated dosing in the metabolic 
pathways. 
The amount of data in pregnant patients was small and only day1 data was available. To predict the 
nonlinear changes in exposure with repeated dosing, AUC increases with repeated dosing had to be 
extrapolated from literature data. Additionally, only low dose, i.e. 40 mg, data was available for the 
pregnant patients, due to which exposure changes for higher doses had to be extrapolated from 
literature data. Although this is not ideal, for the purposes of this analysis, we expect that these 
extrapolations have enabled us to do a rough comparison of pregnant exposures with those of the 
preclinical study by Onda et al. 
In non-pregnant subjects, at higher oral doses of esomeprazole, there is saturation of clearance and 
increase in bioavailability. However, for simplicity, the expected increase in exposure with dose 
escalation and with repeated dosing for all the simulated scenarios was put as an effect only on 
bioavailability. This could mean that the shape of the pharmacokinetic profile has not been 
adequately captured and could possibly underestimate the increase in AUC simulated for scenario 
two and scenario three if auto-inhibition effect on clearance is significant. On the other hand, it was 
also observed that for oral 40 mg esomeprazole, oral AUC is similar to IV AUC at steady state, 




This shows that our simulated scenarios are rather optimistically overestimating the increase in 
exposure. 
In vitro-in vivo extrapolation is a difficult task, and it is inevitable that a number of unknown factors 
that cause differences between the in vitro experiment and the human body cannot be correctly 
adjusted for. In this analysis, in comparing preclinical exposure with clinical exposure we attempted 
to adjust for protein binding and estimated the effect of esomeprazole degradation. This was done 
based on retrospective information obtained from different sources and was not an exact 
extrapolation. Additionally, it is unknown which pharmacokinetic parameter, i.e. Cmax or AUC, is 
related to the efficacy of PPIs in preeclampsia. The simulations show that the preclinical target is 
more achievable if the pharmacokinetic metric which is linked to effect is Cmax. In the preclinical 
study, they incubated tissues with esomeprazole at a concentration of 17.3 mg/L, then performed 
measurements of efficacy after 24 hours. Since it is unclear whether incubation time is an important 
component of efficacy, we considered both the AUC over 24 hours of incubation and the 
instantaneous concentration as Cmax. 
These limitations indicate that further research is required to make decisions on dosage regimen of 
esomeprazole for preeclampsia. Further research is needed both in the form of preclinical studies 
and pharmacokinetic-pharmacodynamic modelling to identify the target pharmacokinetic metric. 
Preclinical studies with different duration could investigate how efficacy changes with different 
experimental conditions, i.e. by exposing placental tissue to esomeprazole over varying incubation 
periods and observing the effect over longer time. Identifying the type of binding esomeprazole has 
with the preeclampsia target will be useful to make dosing decisions. If binding with target is 
covalent, a once-off high concentration could be enough to result in effect for days. In such a 
scenario, the intravenous route of administration would be preferred because higher peak 
concentrations could be achieved, and less frequent dosing would be required. Further investigation 
is also needed to investigate whether any of the metabolites of esomeprazole show efficacy in 
preeclampsia. 
Another alternative also needs to be explored going forward, which is that perhaps a PPI other   than 
esomeprazole could be investigated. Although esomeprazole was chosen from the in vitro 
experiment because of its high potency, there might be some merit in looking at the other PPIs that 




A population pharmacokinetic model of esomeprazole after single 40 mg dose was developed for 
patients with early-onset preeclampsia from the preeclampsia intervention with esomeprazole (PIE) 
trial. Vd/F and CL/F derived from this model were higher than those previously reported for healthy 
subjects.  
Metabolite-to-parent ratio comparisons between pregnant patients and non-pregnant healthy 
subjects were performed. These showed higher AUCsulf/AUCeso in pregnant patients compared to 
day 1 and day 5 in non-pregnant subjects. AUChyd/AUCeso was lower in pregnant patients than in 
non-pregnant on day one while it was similar to that in non-pregnant on day five. These ratios 
indicate that in pregnancy, metabolism has been shifted to the CYP3A4 pathway which means the 
nonlinear pharmacokinetic changes with repeated dosing are not expected to be present in the 
pregnant patients to the same extent as in non-pregnant subjects. 
Cmax and AUC0-24 obtained in pregnant women were compared with those from the in vitro 
preclinical studies where esomeprazole showed efficacy for preeclampsia after adjusting for protein 
binding. Cmax and AUC0-24 obtained from the in vitro study were 25-fold and 70-fold higher than 
those in the pregnant patients.  
 Furthermore, simulations were performed with the model for higher doses of esomeprazole and 
these showed that that the preclinical target concentration and exposure could not be achieved with 
the highest dose that has been clinically used for esomeprazole. 
Further studies are required to investigate the pharmacokinetic marker that best describes the 
relation between concentration and effect. 
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